(−)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release
Identifieur interne : 001976 ( Main/Exploration ); précédent : 001975; suivant : 001977(−)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release
Auteurs : Seiichiro Shimazu [Japon] ; Kazue Takahata [Japon] ; Hiroshi Katsuki [Japon] ; Hiroko Tsunekawa [Japon] ; Akie Tanigawa [Japon] ; Fumio Yoneda [Japon] ; Joseph Knoll [Hongrie] ; Akinori Akaike [Japon]Source :
- European Journal of Pharmacology [ 0014-2999 ] ; 2001.
Abstract
“Catecholaminergic and serotoninergic activity enhancer” effects are newly found mechanisms of action of a class of compound that enhance impulse propagation-mediated release of catecholamines and serotonin in the brain. In the present study, (−)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [(−)-BPAP HCl], a compound with selective and potent “catecholaminergic and serotoninergic activity enhancer” effects, was tested for its efficacy to potentiate locomotor activity in normal rats and to attenuate hypolocomotion in reserpine-treated rats. (−)-BPAP HCl potentiated locomotor activity in non-habituated rats during a 2-h observation period dose-dependently (0.3–10 mg/kg). (−)-BPAP HCl (1–3 mg/kg) was also effective to reverse reserpine-induced hypolocomotion. The effects of (−)-BPAP HCl in normal and reserpine-treated rats were attenuated by the dopamine D1 receptor antagonist, R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH 23390), suggesting that the effects of (−)-BPAP HCl were mediated by activation of the dopaminergic system. In addition, the administration of (−)-BPAP HCl increased ipsilateral turning in unilaterally 6-hydroxydopamine-lesioned rats, implying presynaptic activation of nigrostriatal dopaminergic terminals by (−)-BPAP HCl. Furthermore, although antiparkinsonian agents, such as apomorphine and amantadine, failed to improve reserpine-induced ptosis, (−)-BPAP HCl significantly improved ptosis. These findings suggested that a “catecholaminergic and serotoninergic activity enhancer” compound, (−)-BPAP, stimulates motor function in rats and improves motor deficits in animal models of Parkinson's disease due to its ability to induce dopamine release.
Url:
DOI: 10.1016/S0014-2999(01)01040-8
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>(−)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release</title><author><name sortKey="Shimazu, Seiichiro" sort="Shimazu, Seiichiro" uniqKey="Shimazu S" first="Seiichiro" last="Shimazu">Seiichiro Shimazu</name></author><author><name sortKey="Takahata, Kazue" sort="Takahata, Kazue" uniqKey="Takahata K" first="Kazue" last="Takahata">Kazue Takahata</name></author><author><name sortKey="Katsuki, Hiroshi" sort="Katsuki, Hiroshi" uniqKey="Katsuki H" first="Hiroshi" last="Katsuki">Hiroshi Katsuki</name></author><author><name sortKey="Tsunekawa, Hiroko" sort="Tsunekawa, Hiroko" uniqKey="Tsunekawa H" first="Hiroko" last="Tsunekawa">Hiroko Tsunekawa</name></author><author><name sortKey="Tanigawa, Akie" sort="Tanigawa, Akie" uniqKey="Tanigawa A" first="Akie" last="Tanigawa">Akie Tanigawa</name></author><author><name sortKey="Yoneda, Fumio" sort="Yoneda, Fumio" uniqKey="Yoneda F" first="Fumio" last="Yoneda">Fumio Yoneda</name></author><author><name sortKey="Knoll, Joseph" sort="Knoll, Joseph" uniqKey="Knoll J" first="Joseph" last="Knoll">Joseph Knoll</name></author><author><name sortKey="Akaike, Akinori" sort="Akaike, Akinori" uniqKey="Akaike A" first="Akinori" last="Akaike">Akinori Akaike</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:26C4BBEA3ABF6275A11129CC2926F2A7EDED7E0B</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S0014-2999(01)01040-8</idno><idno type="url">https://api.istex.fr/document/26C4BBEA3ABF6275A11129CC2926F2A7EDED7E0B/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002833</idno><idno type="wicri:Area/Main/Curation">002487</idno><idno type="wicri:Area/Main/Exploration">001976</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">(−)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release</title><author><name sortKey="Shimazu, Seiichiro" sort="Shimazu, Seiichiro" uniqKey="Shimazu S" first="Seiichiro" last="Shimazu">Seiichiro Shimazu</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Institute of Research and Development, Fujimoto Pharmaceutical Corporation, 1-3-40 Nishiotsuka, Matsubara, Osaka 580-8503</wicri:regionArea><wicri:noRegion>Osaka 580-8503</wicri:noRegion></affiliation></author><author><name sortKey="Takahata, Kazue" sort="Takahata, Kazue" uniqKey="Takahata K" first="Kazue" last="Takahata">Kazue Takahata</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Institute of Research and Development, Fujimoto Pharmaceutical Corporation, 1-3-40 Nishiotsuka, Matsubara, Osaka 580-8503</wicri:regionArea><wicri:noRegion>Osaka 580-8503</wicri:noRegion></affiliation></author><author><name sortKey="Katsuki, Hiroshi" sort="Katsuki, Hiroshi" uniqKey="Katsuki H" first="Hiroshi" last="Katsuki">Hiroshi Katsuki</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida-Shimoadachi-cho, Sakyo, Kyoto 606-8501</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author><author><name sortKey="Tsunekawa, Hiroko" sort="Tsunekawa, Hiroko" uniqKey="Tsunekawa H" first="Hiroko" last="Tsunekawa">Hiroko Tsunekawa</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Institute of Research and Development, Fujimoto Pharmaceutical Corporation, 1-3-40 Nishiotsuka, Matsubara, Osaka 580-8503</wicri:regionArea><wicri:noRegion>Osaka 580-8503</wicri:noRegion></affiliation></author><author><name sortKey="Tanigawa, Akie" sort="Tanigawa, Akie" uniqKey="Tanigawa A" first="Akie" last="Tanigawa">Akie Tanigawa</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Institute of Research and Development, Fujimoto Pharmaceutical Corporation, 1-3-40 Nishiotsuka, Matsubara, Osaka 580-8503</wicri:regionArea><wicri:noRegion>Osaka 580-8503</wicri:noRegion></affiliation></author><author><name sortKey="Yoneda, Fumio" sort="Yoneda, Fumio" uniqKey="Yoneda F" first="Fumio" last="Yoneda">Fumio Yoneda</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Institute of Research and Development, Fujimoto Pharmaceutical Corporation, 1-3-40 Nishiotsuka, Matsubara, Osaka 580-8503</wicri:regionArea><wicri:noRegion>Osaka 580-8503</wicri:noRegion></affiliation></author><author><name sortKey="Knoll, Joseph" sort="Knoll, Joseph" uniqKey="Knoll J" first="Joseph" last="Knoll">Joseph Knoll</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Pharmacology, Semmelweis University of Medicine, Budapest P.O.B. 370, H-1445</wicri:regionArea><wicri:noRegion>H-1445</wicri:noRegion></affiliation></author><author><name sortKey="Akaike, Akinori" sort="Akaike, Akinori" uniqKey="Akaike A" first="Akinori" last="Akaike">Akinori Akaike</name><affiliation wicri:level="1"><country wicri:rule="url">Japon</country></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida-Shimoadachi-cho, Sakyo, Kyoto 606-8501</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Pharmacology</title><title level="j" type="abbrev">EJP</title><idno type="ISSN">0014-2999</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">421</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="181">181</biblScope><biblScope unit="page" to="189">189</biblScope></imprint><idno type="ISSN">0014-2999</idno></series><idno type="istex">26C4BBEA3ABF6275A11129CC2926F2A7EDED7E0B</idno><idno type="DOI">10.1016/S0014-2999(01)01040-8</idno><idno type="PII">S0014-2999(01)01040-8</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0014-2999</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">“Catecholaminergic and serotoninergic activity enhancer” effects are newly found mechanisms of action of a class of compound that enhance impulse propagation-mediated release of catecholamines and serotonin in the brain. In the present study, (−)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [(−)-BPAP HCl], a compound with selective and potent “catecholaminergic and serotoninergic activity enhancer” effects, was tested for its efficacy to potentiate locomotor activity in normal rats and to attenuate hypolocomotion in reserpine-treated rats. (−)-BPAP HCl potentiated locomotor activity in non-habituated rats during a 2-h observation period dose-dependently (0.3–10 mg/kg). (−)-BPAP HCl (1–3 mg/kg) was also effective to reverse reserpine-induced hypolocomotion. The effects of (−)-BPAP HCl in normal and reserpine-treated rats were attenuated by the dopamine D1 receptor antagonist, R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH 23390), suggesting that the effects of (−)-BPAP HCl were mediated by activation of the dopaminergic system. In addition, the administration of (−)-BPAP HCl increased ipsilateral turning in unilaterally 6-hydroxydopamine-lesioned rats, implying presynaptic activation of nigrostriatal dopaminergic terminals by (−)-BPAP HCl. Furthermore, although antiparkinsonian agents, such as apomorphine and amantadine, failed to improve reserpine-induced ptosis, (−)-BPAP HCl significantly improved ptosis. These findings suggested that a “catecholaminergic and serotoninergic activity enhancer” compound, (−)-BPAP, stimulates motor function in rats and improves motor deficits in animal models of Parkinson's disease due to its ability to induce dopamine release.</div></front></TEI><affiliations><list><country><li>Hongrie</li><li>Japon</li></country><region><li>Région du Kansai</li></region><settlement><li>Kyoto</li></settlement><orgName><li>Université de Kyoto</li></orgName></list><tree><country name="Japon"><noRegion><name sortKey="Shimazu, Seiichiro" sort="Shimazu, Seiichiro" uniqKey="Shimazu S" first="Seiichiro" last="Shimazu">Seiichiro Shimazu</name></noRegion><name sortKey="Akaike, Akinori" sort="Akaike, Akinori" uniqKey="Akaike A" first="Akinori" last="Akaike">Akinori Akaike</name><name sortKey="Akaike, Akinori" sort="Akaike, Akinori" uniqKey="Akaike A" first="Akinori" last="Akaike">Akinori Akaike</name><name sortKey="Katsuki, Hiroshi" sort="Katsuki, Hiroshi" uniqKey="Katsuki H" first="Hiroshi" last="Katsuki">Hiroshi Katsuki</name><name sortKey="Takahata, Kazue" sort="Takahata, Kazue" uniqKey="Takahata K" first="Kazue" last="Takahata">Kazue Takahata</name><name sortKey="Tanigawa, Akie" sort="Tanigawa, Akie" uniqKey="Tanigawa A" first="Akie" last="Tanigawa">Akie Tanigawa</name><name sortKey="Tsunekawa, Hiroko" sort="Tsunekawa, Hiroko" uniqKey="Tsunekawa H" first="Hiroko" last="Tsunekawa">Hiroko Tsunekawa</name><name sortKey="Yoneda, Fumio" sort="Yoneda, Fumio" uniqKey="Yoneda F" first="Fumio" last="Yoneda">Fumio Yoneda</name></country><country name="Hongrie"><noRegion><name sortKey="Knoll, Joseph" sort="Knoll, Joseph" uniqKey="Knoll J" first="Joseph" last="Knoll">Joseph Knoll</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001976 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001976 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:26C4BBEA3ABF6275A11129CC2926F2A7EDED7E0B
|texte= (−)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release
}}
| This area was generated with Dilib version V0.6.23. |  |